NEW YORK (AP) ¿ A Robert W. Baird & Co analyst upgraded shares of Varian Medical Systems Inc. Monday, citing his outlook for the medical device maker's sales. Jeff D. Johnson upgraded the stock to "Outperform" from "Neutral" and boosted the price target to $49 from $41 citing a better outlook for demand in the European radiation therapy market. The company focuses on cancer therapy systems. Other factors for the upgrade include growing demand in developing markets and economic improvements. "Reasons we heard for why European demand could remain relatively stable to only slightly softer in 2010 versus 2009 were varied," Johnson said, citing government funding helping to support the industry, along with more budget protection for radiation and cancer care as compared to other health care areas in a number of countries. Meanwhile, new products, such as the Unique bundled radiotherapy option, could help drive sales. Also, signs of an improving economy lessen the overall concern about hospital budgets, he added. Shares of Varian closed at $40.83 Friday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Short-Term Versus Long-Term Investing: Which Is the Better Investment?
Should investors consider short-term or long-term investing when they compile their portfolio? Here's what Carol Schleif, deputy chief investment officer at Abbot Downing.
HP Inc. Shares Rise After Company Beats on Earnings and Revenue
The company also slightly raised its earnings per share guidance for the year.
Jim Cramer Explains What a Trade War With China Means for Tesla
Tesla stock continues to tumble. Jim Cramer opines if ongoing trade tensions with China are to blame.